K T Park1, Aaron Sin, May Wu, Dorsey Bass, Jay Bhattacharya. 1. *Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children's Hospital; †Center for Health Policy/Primary Care Outcomes Research; ‡School of Medicine; §Department of Pharmacy, Lucile Packard Children's Hospital; and ‖Departments of Medicine and Economics, Stanford University, Stanford, California.
Abstract
BACKGROUND: Utilization trends and health effects of infliximab and adalimumab in inflammatory bowel disease (IBD) are incompletely understood. We aimed to describe utilization trends of these 2 anti-tumor necrosis factor (TNF) agents, determine the correlation between utilization with rates of hospitalization and surgery and describe differences in use between adults and children. METHODS: Longitudinal data were analyzed for drug utilization, hospitalization, and abdominal surgery. Descriptive statistics were used to show trends, and utilization quotients were compared for standardization. Multivariate logistic regression analysis assessed the association between drug use and rates of hospitalization and surgery. RESULTS: Four hundred thirty-eight pediatric and 2514 adult patients with IBD generated a total of 51,882 inpatient and outpatient encounters, representing 1185 Crohn's disease, 1531 ulcerative colitis, and 236 indeterminate colitis patients. From 2007 through 2012, utilization quotients declined for hospitalization but remained unchanged for surgery; adalimumab saw a 3-fold increase, despite continued dominance of infliximab. Median band and mean fitted plots showed downward hospitalization trends from 2006 to 2012. Utilization of infliximab peaked in 2008, Q4 with gradual decline to 2012, Q2; and adalimumab showed moderate increased utilization since 2007, Q1. Use of infliximab (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.70-0.83) and adalimumab (OR, 0.79; 95% CI, 0.72-0.87) was associated with decreased hospitalization risk but not associated with reduced abdominal surgery risk. Children had increased hospitalization (OR, 2.68; 95% CI, 2.49-2.88) but decreased risk for abdominal surgery (OR, 0.57; 95% CI, 0.46-0.70). CONCLUSIONS: Current infliximab use remains substantially greater than adalimumab use, despite recent increased use of adalimumab. Although trends for hospitalization for IBD are decreasing, it is not reflected in abdominal surgery rates in a tertiary IBD referral center.
BACKGROUND: Utilization trends and health effects of infliximab and adalimumab in inflammatory bowel disease (IBD) are incompletely understood. We aimed to describe utilization trends of these 2 anti-tumor necrosis factor (TNF) agents, determine the correlation between utilization with rates of hospitalization and surgery and describe differences in use between adults and children. METHODS: Longitudinal data were analyzed for drug utilization, hospitalization, and abdominal surgery. Descriptive statistics were used to show trends, and utilization quotients were compared for standardization. Multivariate logistic regression analysis assessed the association between drug use and rates of hospitalization and surgery. RESULTS: Four hundred thirty-eight pediatric and 2514 adult patients with IBD generated a total of 51,882 inpatient and outpatient encounters, representing 1185 Crohn's disease, 1531 ulcerative colitis, and 236 indeterminate colitispatients. From 2007 through 2012, utilization quotients declined for hospitalization but remained unchanged for surgery; adalimumab saw a 3-fold increase, despite continued dominance of infliximab. Median band and mean fitted plots showed downward hospitalization trends from 2006 to 2012. Utilization of infliximab peaked in 2008, Q4 with gradual decline to 2012, Q2; and adalimumab showed moderate increased utilization since 2007, Q1. Use of infliximab (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.70-0.83) and adalimumab (OR, 0.79; 95% CI, 0.72-0.87) was associated with decreased hospitalization risk but not associated with reduced abdominal surgery risk. Children had increased hospitalization (OR, 2.68; 95% CI, 2.49-2.88) but decreased risk for abdominal surgery (OR, 0.57; 95% CI, 0.46-0.70). CONCLUSIONS: Current infliximab use remains substantially greater than adalimumab use, despite recent increased use of adalimumab. Although trends for hospitalization for IBD are decreasing, it is not reflected in abdominal surgery rates in a tertiary IBD referral center.
Authors: Chaitanya Pant; Michael P Anderson; Abhishek Deshpande; John E Grunow; Judith A O'Connor; Jessica R Philpott; Thomas J Sferra Journal: J Investig Med Date: 2013-08 Impact factor: 2.895
Authors: M Chaparro; J Panés; V García; O Merino; P Nos; E Domènech; M Peñalva; E García-Planella; M Esteve; J Hinojosa; M Andreu; F Muñoz; A Gutiérrez; J L Mendoza; J Barrio; M Barreiro-de; I Vera; P Vilar; J L Cabriada; M A Montoro; X Aldeguer; C Saro; J P Gisbert Journal: Inflamm Bowel Dis Date: 2011-05-25 Impact factor: 5.325
Authors: Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar Journal: Gut Date: 2011-01-05 Impact factor: 23.059
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Carlos Taxonera; Luis Rodrigo; Francesc Casellas; Xavier Calvet; Federico Gómez-Camacho; Daniel Ginard; Manuel Castro; Luisa Castro; Marta Ponce; Pilar Martínez-Montiel; Elena Ricart; Javier P Gisbert; Antonio López-San Román; José M Morales; Miguel A Casado Journal: J Clin Gastroenterol Date: 2009 Nov-Dec Impact factor: 3.062
Authors: Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682
Authors: A Oussalah; C Laclotte; J-B Chevaux; M Bensenane; A Babouri; A-A Serre; T Boucekkine; X Roblin; M-A Bigard; L Peyrin-Biroulet Journal: Aliment Pharmacol Ther Date: 2008-07-24 Impact factor: 8.171
Authors: Beverley Kok; Erica L W Lester; William M Lee; A James Hanje; R Todd Stravitz; Safwat Girgis; Vaishali Patel; Joshua R Peck; Christopher Esber; Constantine J Karvellas Journal: Dig Dis Sci Date: 2018-03-21 Impact factor: 3.199
Authors: K T Park; Richard B Colletti; David T Rubin; Bal K Sharma; Amy Thompson; Andrew Krueger Journal: Am J Gastroenterol Date: 2015-07-21 Impact factor: 10.864
Authors: S Ballou; W Hirsch; P Singh; V Rangan; J Nee; J Iturrino; T Sommers; J Zubiago; N Sengupta; A Bollom; M Jones; A C Moss; S N Flier; A S Cheifetz; A Lembo Journal: Aliment Pharmacol Ther Date: 2018-02-07 Impact factor: 8.171
Authors: Faith D Ihekweazu; Tatiana Fofanova; Ryan Palacios; Avanthi Ajjarapu; Lina Karam; Adam M Vogel; J R Rodriguez; Richard Kellermayer Journal: J Pediatr Surg Date: 2020-02-03 Impact factor: 2.545
Authors: Aaron T Sin; Jennifer L Damman; David A Ziring; Elizabeth E Gleghorn; Manuel G Garcia-Careaga; Roberto R Gugig; Anna K Hunter; Jennifer C Burgis; Dorsey M Bass; K T Park Journal: Inflamm Bowel Dis Date: 2015-06 Impact factor: 5.325
Authors: Joshua C Berkowitz; Joanna Stein-Fishbein; Sundas Khan; Richard Furie; Keith S Sultan Journal: World J Gastrointest Pharmacol Ther Date: 2018-02-06